Arbutus Biopharma CorporationABUS
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · arbutusbio.com
Clinical-stage biopharmaceutical company focused on chronic hepatitis B (imdusiran, AB-101), with significant lipid-nanoparticle patent licensing and enforcement economics through Genevant. British Columbia-incorporated, headquartered in Warminster, Pennsylvania.
Key ratios
FCF / Sales
-281.5%2025
2024
-1053.8%2023
-479.3%
Net margin
84.0%TTM
2025
-237.9%
ROA
49.2%TTM
2025
-14.9%2024
-31.7%2023
-28.7%
ROE
94.7%TTM
2025
-38.5%2024
-68.8%2023
-60.0%
Revenue growth
128.2%2025
2024
-66.0%2023
-53.5%
Recent news
Arbutus Commences US$230 Million Modified "Dutch Auction" Tender Offer of its Common Shares
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified "Dutch Auction" Tender Offer
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Track ABUS in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer